View in EDS HTML Full Text PDF Full Text

Safety and tolerability of a 90‐minute rapid infusion of Sandoz biosimilar rituximab in B‐cell lymphoproliferative disorders in a real‐world setting.

Saved in:
Bibliographic Details
Title: Safety and tolerability of a 90‐minute rapid infusion of Sandoz biosimilar rituximab in B‐cell lymphoproliferative disorders in a real‐world setting.
Authors: Muntañola, Ana1 (AUTHOR), Arguiñano‐Pérez, José María2 (AUTHOR), Dávila, Julio3 (AUTHOR), de Villambrosia, Sonia González4 (AUTHOR), Carpio, Cecilia5,6 (AUTHOR), Jiménez‐Ubieto, Ana7 (AUTHOR), Salar, Antonio8,9,10 (AUTHOR) asalar@psmar.cat
Source: CTS: Clinical & Translational Science. Feb2023, Vol. 16 Issue 2, p305-312. 8p.
Database: Academic Search Ultimate
Full text is not displayed to guests.
Description
ISSN:17528054
DOI:10.1111/cts.13450